Review
Version 2
Preserved in Portico This version is not peer-reviewed
The Novelty of mRNA Vaccines and Potential Harms: A Scoping Review
Version 1
: Received: 1 January 2023 / Approved: 9 January 2023 / Online: 9 January 2023 (01:54:33 CET)
Version 2 : Received: 11 January 2023 / Approved: 12 January 2023 / Online: 12 January 2023 (03:16:56 CET)
Version 2 : Received: 11 January 2023 / Approved: 12 January 2023 / Online: 12 January 2023 (03:16:56 CET)
A peer-reviewed article of this Preprint also exists.
Halma, M.T.; Rose, J.; Lawrie, T. The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review. J 2023, 6, 220-235. Halma, M.T.; Rose, J.; Lawrie, T. The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review. J 2023, 6, 220-235.
Abstract
Pharmacovigilance databases are showing evidence of injury in the context of the COVID-19 modified mRNA shots. According to recent publications, adverse event reports linked to the mRNA COVID-19 products largely point to the spike protein as an aetiological agent of adverse events, but we propose that the platform itself may be culpable. To assess the safety of current and future mRNA vaccines, further analysis on the risks due to the platform itself, and not specifically the expressed antigen. If harm can be exclusively and conclusively attributed to the spike protein, then it is possible that future mRNA vaccines expressing other antigens will be safe. If harms are attributable to the platform itself, then regardless of the toxicity, or lack thereof, of the chosen payload therein, the platform may be inherently unsafe, pending modification. In this work, we examine previous studies of RNA-based delivery by a lipid nanoparticle and break down the possible etiological elements of harm.
Keywords
COVID-19 vaccination; mRNA vaccines; Clinical Trials; Safety Assessment; Novel Technologies; Spike protein
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (2)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: Matthew Halma
Commenter's Conflict of Interests: Author
Commenter: John Philip Moore
The commenter has declared there is no conflict of interests.
A balanced review of mRNA vaccines would include all of the dozens of publications on the overall safety of the Covid-19 vaccines both before and above their authorization/approval in multiple countries. This publications invariably show that these Covid-19 mRNA vaccines have an excellent safety profile. Yes, there are legitimate associations between these mRNA vaccines and myocarditis, particularly in young men. These safety signals exist, and are universally acknowledged by medical science. But the side effects are very rare, and are mostly rapidly resolved. In addition, Covid-19 is associated with a much higher prevalence of myocarditis (as well as other health dangers), so the net effect of the mRNA vaccines is to reduce the incidence of such complications. An additional point a balanced review would include is efficacy - the many millions of lives and trillions of dollars the mRNA vaccines have solved worldwide. Accordingly, we encourage readers to take these points into account when reading this article.
We also suggest that readers should do their own due diligence on the qualifications of the authors in relevant areas of medical science, and their membership of groups such as, but not limited to, the World Council for Health. That organization promotes the use of Ivermectin and other questionable and unproven interventions against Covid-19. Some of its members associate with conspiracy theorists such as those who believe Covid-19 is spread by 5G networks and promote an anti-vaccination agenda.
This comment is co-authored by Gregg Gonsalves of Yale University.
Neither co-author has a conflict of interest to declare. We receive no funding or other income from any vaccine company.